John Corboy, MD, MA

Professional Titles

• Charles Elliot Morris Chair in Neurology
• Executive Vice Chair of Neurology
• Co-Director, Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus
• Director, Neuroimmunology/MS Fellowship
• Section Chief, Neuroimmunology

Research Interests

Publications

• Haug A, Mahalingam R, Cohrs RJ, Schmid DS, Corboy JR, Gilden D. Recurrent polymorphonuclear pleocytosis with increased red blood cells caused by varicella zoster virus infection of the central nervous system. Journal of the Neurological Sciences: 19-FEB-2010 DOI information: 10.1016/j.jns.2010.01.019
• Miravalle A and Corboy JR. Five new things in multiple sclerosis. Neurology: Clinical Practice, 2010 Nov 2;75(18 Suppl 1):S22-7.
• Freeman WD, Nolte CM, Matthew BR, Coleman C, and Corboy JR. Results of the American Academy of Neurology Resident Survey. Neurology, 2011, in press.
• Bainbridge JL and Corboy JR. Multiple Sclerosis, in Pharmacotherapy, A Pathophysiologic Approach, Eighth Edition, ed JT DiPiro, et al, McGraw-Hill, 2011 (pending).
• Freeman WD, Nolte CM, Matthew BR, Coleman C, and Corboy JR. Results of the American Academy of Neurology Resident Survey. Neurology. 2011 Mar 29;76(13):e61-7.
• Hebert JR, Corboy JR, Manago MM, Schenkman M. Effects of Vestibular Rehabilitation on Multiple Sclerosis–Related Fatigue and Upright Postural Control: A Randomized Controlled Trial. Physical Therapy, 2011; 98:1-18
• Nair KV, Corboy J, Kahler K, Allen R, et al. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis. Expert Rev. Neurother, 2011; 11(6): 787–798.
• 5. Waldman AT, Gorman MP, Rensel MR, Austin TE, Hertz DP, Kuntz NL; Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol. 2011 Jun;26(6):675-82. Epub 2011 Apr 25.
• Bainbridge JL and Corboy JR. Multiple Sclerosis, in Pharmacotherapy, A Pathophysiologic Approach, Eighth Edition, ed JT DiPiro, et al, McGraw-Hill, 2011 pp963-978
• Kleinschmidt-Demasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab. J Neuropathol Exp Neurol. 2012 Jul;71(7):604-17
• Campbell JD, McQueen RB, Miravalle A, Corboy J, Vollmer T, Nair K. Comparative effectiveness of early natalizumab treatment in JC virus negative relapsing-remitting multiple sclerosis. Accepted American Journal of Managed Care, April, 2013
• Waid DM, Schreiner T, Vaitaitis G, Carter JR, Corboy JR, Wagner DH Jr. Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. J Neuroimmunol. 2014 Mar 15. [Epub ahead of print] PubMed PMID: 24690203
• Lafosse JM, Mitchell SM, Corboy JR, Filley CM. The nature of verbal memory impairment in multiple sclerosis: a list-learning and meta-analytic study. J Int Neuropsychol Soc. 2013 Oct;19(9):995-1008. PubMed PMID: 24059259
• Campbell JD, Ghushchyan V, McQueen RB, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J, Miravalle A, Schreiner T, Porter V, Nair KV. Burden of multiple sclerosis on direct, indirect costs and quality of life: national US estimates. Multiple Sclerosis and Related Disorders. 2014; 3(2): 227-236.
• Waid DM, Schreiner T, Vaitaitis G, Carter JR, Corboy JR, Wagner DH Jr. Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. J Neuroimmunol. 2014 Mar 15. pii: S0165-5728(14)00073-3. doi: 10.1016/j.jneuroim.2014.03.009. [Epub ahead of print]
• Larsen DP, Butler AC, Aung WY, Corboy JR, Friedman DI, and Sperling MR. The effects of test-enhanced learning on long-term retention in AAN annual meeting courses. 2014 Accepted, Neurology
• McQueen R, Livingston T, Vollmer T, Corboy J, Buckley B, Allen R, Nair K, and Campbell J. Increased relapse activity for multiple sclerosis natalizumab users who become non-persistent: a retrospective study. Journal of Managed Care & Specialty Pharmacy 2015 in press
• Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study. Multiple Sclerosis and Related Disorders Volume 3, Issue 6, Pages 696-704 (November 2014) DOI:10.1016/j.msard.2014.08.002
• Solomon AJ, Klein EP, Corboy JR, Bernat JL. Patient Perspectives on Physician Conflict of Interest in Industry-Sponsored Clinical Trials for Multiple Sclerosis Therapeutics. Multiple Sclerosis, accepted 2015
• Mattson DH, Lisak RP, Jones DE, Corboy JR, Larson R, Gronseth G, Getchius TS, Langer-Gould A, Langer-Gould AM, Gronseth GS, Larson R, Getchius TS. The American Academy of Neurology's top five Choosing Wisely recommendations. Neurology. 2013 Sep 10;81(11):1022-3. PubMed PMID: 24019388
• Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Am J Manag Care. 2013 Apr;19(4):278-85. PubMed PMID: 23725360
• Hebert JR, Corboy JR. The association between multiple sclerosis-related fatigue and balance as a function of central sensory integration. Gait Posture. 2013 May;38(1):37-42. PubMed PMID: 23200463
• Kister I, Corboy JR. Reducing costs while enhancing quality of care in MS. Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003113. [Epub ahead of print] PMID:27590294
• Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen R, and Campbell JD. Multiple Sclerosis Prevalence in the United States Commercially Insured Population. Neurology. 2016 Mar 15;86(11):1014-21. doi: 10.1212/WNL.0000000000002469. Epub 2016 Feb 17.
• Govindarajan KA, Datta S, Hasan KM, Choi S, Rahbar MH, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA; MRI Analysis Center at Houston, The CombiRx Investigators Group. Effect of in-painting on cortical thickness measurements in multiple sclerosis: A large cohort study. Hum Brain Mapp. 2015 Oct;36(10):3749-60. doi: 10.1002/hbm.22875. Epub 2015 Jun 19.PMID:26096844
• Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29.PMID:26621682
• Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen R, and Campbell JD. Multiple Sclerosis Prevalence in the United States Commercially Insured Population. Neurology. 2016 Mar 15;86(11):1014-21. doi: 10.1212/WNL.0000000000002469. Epub 2016 Feb 17.
• Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neurology. 2016 Mar 15;86(11):1014-21. doi: 10.1212/WNL.0000000000002469. Epub 2016 Feb 17.
• Klein E, Solomon AJ, Corboy J, Bernat J. Physician compensation for industry-sponsored clinical trials in multiple sclerosis influences patient trust. Mult Scler Relat Disord. 2016 Jul;8:4-8. doi: 10.1016/j.msard.2016.04.001. Epub 2016 Apr 11
• Kister I, Corboy JR. Reducing costs while enhancing quality of care in MS. Neurology. 2016 Oct 11;87(15):1617-1622: 10.1212/WNL.0000000000003113. [Epub ahead of print] PMID:27590294
• Corboy JR. Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS - Commentary. Mult Scler. 2017 Jun 1:1352458517717809. doi: 10.1177/1352458517717809. [Epub ahead of print] No abstract available. PMID: 28673113
• Hardy TA, Corboy JR, Weinshenker BG. Baló concentric sclerosis evolving from apparent tumefactive demyelination. Neurology. 2017 May 30;88(22):2150-2152. doi: 10.1212/WNL.0000000000003990. Epub 2017 May 3. No abstract available. PMID: 28468846
• Solomon AJ, Corboy JR. The tension between early diagnosis and misdiagnosis of multiple sclerosis. Nat Rev Neurol. 2017 Sep;13(9):567-572. doi:10.1038/nrneurol.2017.106. Epub 2017 Aug 11. Review. No abstract available. PMID: 28799551
• Hassani A, Corboy JR, Al-Salam S, Khan G. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS One. 2018 Feb 2;13(2):e0192109. doi: 10.1371/journal.pone.0192109. eCollection 2018.
• Hebert JR, Corboy JR, Vollmer T, Forster JE, Schenkman M. Efficacy of Balance and . Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS). Neurology. 2018 Feb 27;90(9):e797-e807. doi: 10.1212/WNL.0000000000005013. Epub 2018 Jan 31. PMID: 29386274.
• Corboy JR, Weinshenker BG, Wingerchuk DM. Comment on the 2018 American Academy of Neurology guidelines on disease-modifying therapies in multiple sclerosis. Published electronically ahead of print, Neurology. 2018 2018 Jun 12;90(24):1106-1112. pii: 10.1212/WNL.0000000000005574. doi: 10.1212/WNL.0000000000005574. [Epub ahead of print] Review. PMID: 29685920
• Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E. The Impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectivemness outcomes in multiple sclerosis. J Neurol Sci. 2018 Jul 15;390: 89- 93. PMID:29801915
• Gould JR, Reineberg AE, Cleland BT, Knoblauch KE, Clinton GK, Banich MT, Corboy JR, Enoka RM. Adjustments in Torque Steadiness During Fatiguing Contractions Are Inversely Correlated With IQ in Persons With Multiple Sclerosis. Front Physiol. 2018 Oct 17;9:1404. doi: 10.3389/fphys.2018.01404. eCollection 2018. PMID: 30386250
• Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE. Autologous hematopoietic stem cell transplantation for treatment-refractory relapsing multiple sclerosis: Position statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 Feb 19. pii: S1083-8791(19)30139-9. doi: 10.1016/j.bbmt.2019.02.014. [Epub ahead of print]
• Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollemr T, Alvarez T. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology 2019; 6: pp 252-62
• Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 Feb 12;92(7):e723-e732. doi: 10.1212/WNL.0000000000006916. Epub 2019 Jan 11.PMID: 30635477
• Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019 Sep 17;36:101402. doi: 10.1016/j.msard.2019.101402. [Epub ahead of print. PMID: 31542710
• McGinley MP, Cola PA, Fox RJ, Cohen JA, Corboy JR, Miller D. Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies. Mult Scler. 2019 Aug 1:1352458519867314. doi: 10.1177/1352458519867314. [Epub ahead of print. PMID: 31368401
• Mowry EM, Corboy JR. Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosis. Lancet Neurol. 2019 Sep 3. pii: S1474- 4422(19)30333-3. doi: 10.1016/S1474-4422(19)30333-3. [Epub ahead of print] No abstract available. PMID: 31492653
• Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Oct 15;407:116498. doi: 10.1016/j.jns.2019.116498. [Epub ahead of print] PMID:31644992
• Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies. Gross RH, Corboy JR. Continuum (Minneap Minn). 2019 Jun;25(3):715-735. doi: 10.1212/CON.0000000000000738. Erratum in: Continuum (Minneap Minn). 2019 Aug;25(4):1175. PMID: 31162313
• Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel,RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract. 2018 Aug;8(4):292-301. doi: 10.1212/CPJ.0000000000000487. PMID: 30140580
• Neurol Clin Pract. 2018 Jun;8(3):177-178. doi: 10.1212/CPJ.0000000000000459. Curbside consults join the telemedicine era. Nuwer MR1, Corboy JR1.
• Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170. PMID: 29576505
• Gross R and Corboy JR Monitoring, Switching and Discontinuing DMTs in Relapsing MS. Continuum 2018 (publication pending)
• Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders.Ann Clin Transl Neurol. 2020 Aug 6. doi: 10.1002/acn3.51136. Online ahead of print. PMID: 32767531
• Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 Aug 6. doi: 10.1002/acn3.51111. Online ahead of print. PMID: 32767538
• Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL, Ford C, Weinstock-Guttman B, Bar-Or A, Mientus S, Sienkiewicz D, Zhang Y, Karan R, Tenenbaum N; Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. ASSESS Trial Investigators. JAMA Neurol. 2020 Aug 24:e202950. doi: 10.1001/jamaneurol.2020.2950. Online ahead of print.PMID: 32852530
• Wu Q, Mills EA, Wang Q, Dowling CA, Fisher C, Kirch B, Lundy SK, Fox DA, Mao- Draayer Y. Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis.; AMS04 Study Group.JCI Insight. 2020 Feb 13;5(3). pii: 134251. doi: 10.1172/jci.insight.134251. PMID: 31935197
• Cree BAC, Cutter G, Wolinsky JS, et al SPI2 investigative teams. Safetyand efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2020 Dec;19(12):988-997. doi: 10.1016/S1474-4422(20)30347-1. Epub 2020 Oct 23.PMID: 33222767
• Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL, Ford C, Weinstock-Guttman B, Bar-Or A, Mientus S, Sienkiewicz D, Zhang Y, Karan R, Tenenbaum N; Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. ASSESS Trial Investigators. JAMA Neurol. 2020 Aug 24; 78(1):1-13. doi: 10.1001/jamaneurol.2020.2950. Online ahead of print. PMID: 32852530
• Honce JM, Nair KV, Hoyt BD, Seale RA, Sillau S, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Alvarez E. Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Front Neurol. 2020 Sep 23;11:1045. doi: 10.3389/fneur.2020.01045. eCollection 2020.PMID: 33071934
• Strijbis EMM, Kerbrat A, Corboy JR. Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go? JAMA Neurol. 2021 Jul 1;78(7):787-788. doi: 10.1001/jamaneurol.2021.0764.PMID: 33871561
• Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Jul 24;55:103170. doi: 10.1016/j.msard.2021.103170. Online ahead of print.PMID: 34364034
• Vollmer BL, Wolf AB, Sillau S, Corboy JR, Alvarez E. Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis. Front Neurol. 2021;12:799138. PubMed PMID: 35145470
• Alvarez E, Nair KV, Sillau S, Shelton I, Seale R, Selva S, Corboy J, Vollmer TL. Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions. Mult Scler J Exp Transl Clin. 2022 Jan-Mar;8(1):20552173211069359. PubMed PMID: 35024160
• Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Oct;55:103170. PubMed PMID: 34364034
• Piquet AL, Corboy JR, Vollmer TL. Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211019567. PubMed PMID: 34104219
• Corboy JR, Jones EC, Barbano RL, Anderson DC. 2019-2020: A Message From the Editors to Our Reviewers. Neurol Clin Pract. 2021 Feb;11(1):e1-e5. PubMed PMID: 33968478
• Strijbis EMM, Kerbrat A, Corboy JR. Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go?. JAMA Neurol. 2021 Jul 1;78(7):787-788. PubMed PMID: 33871561
• Vollmer BL, Wolf AB, Sillau S, Corboy JR, Alvarez E. Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis. Front Neurol. 2022 Jan 25;12:799138. doi: 10.3389/fneur.2021.799138. eCollection 2021.PMID: 3514547 85. Shah AA, Wolf AB, Declusin A, Coleman K, Kammeyer R, Khan B, Corboy JR. Challenging Cases in Neuroimmunology. Semin Neurol. 2022 Dec;42(6):695-707. doi: 10.1055/s-0042-1760100. Epub 2023 Jan 23.PMID: 36690027
• Barrera B, Simpson H, Engebretson E, Sillau S, Valdez B, Parra-González J, Winger RC, Epperson LA, Banks A, Pierce K, Spotts M, O'Gean K, Alvarez E, Gross R, Piquet AL, Schreiner T, Corboy JR, Pei J, Vollmer TL, Nair KV. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis. Ann Clin Transl Neurol. 2023 Apr;10(4):579-588. doi: 10.1002/acn3.51745. Epub 2023 Feb 22.PMID: 36811392
• Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, Engebretson E, Gustafson T, Miller AE. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 2023 Jul;22(7):568-577. doi: 10.1016/S1474-4422(23)00154-0.PMID: 37353277
• Shafit-Zagardo B, Sidoli S, Goldman JE, DuBois JC, Corboy JR, Strittmatter SM, Guzik H, Edema U, Arackal AG, Botbol YM, Merheb E, Nagra RM, Graff S. TMEM106B Puncta Is Increased in Multiple Sclerosis Plaques, and Reduced Protein in Mice Results in Delayed Lipid Clearance Following CNS Injury. Cells. 2023 Jun 27;12(13):1734. doi: 10.3390/cells12131734.PMID: 37443768
• Solomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L, Banwell BL, Barkhof F, Corboy JR, Correale J, Fujihara K, Graves J, Harnegie MP, Hemmer B, Lechner-Scott J, Marrie RA, Newsome SD, Rocca MA, Royal W 3rd, Waubant EL, Yamout B, Cohen JA. Differential diagnosis of suspected multiple sclerosis: an updated consensus approach. Lancet Neurol. 2023 Aug;22(8):750-768. doi: 10.1016/S1474-4422(23)00148-5.PMID: 37479377
• Borko TL, Baxter R, Cabrera-Martinez B, Thiruppathi E, Sabalza M, Venkataraman I, Selva S, Rester C, Sillau S, Pastula DM, Bennett JL, Alvarez E, Gross R, Shah A, Kammeyer R, Corboy JR, Kedl RM, Hsieh EWY, Piquet AL. SARS-CoV-2 mRNA vaccination induces an antigen-specific T cell response correlating with plasma interferon-gamma in B cell depleted patients. J Neuroimmunol. 2023 Oct 15;383:578192. doi: 10.1016/j.jneuroim.2023.578192. Epub 2023 Aug 29.PMID: 37666038
• Abstract 1605 ECTRIMS DISCOntinuation of disease modifying therapies in MS (DISCOMS); Primary results of the extension trial

Professional Memberships

• American Neurological Association, Elected Member
• Colorado Society of Clinical Neurologists, 1995-1997 Secretary/Treasurer
• American Academy of Neurology, Fellow 2003

Practice Locations

• University of Colorado Hospital

• Rocky Mountain Multiple Sclerosis Center

Specialty Information

• Neurology, Board Certification (1990)
• Neuroimmunology

• Brain and Nervous System
• Brain and Nervous System - Multiple Sclerosis